Final Laboratory Report PID : 5905991

Name : Mr. JOHN Sex/Age : Male / 52 Years Lab ID : 50526900002

Ref. By : DR.VIJAYALAKSHMI.S M.D SRF ID : Ref. ID :
(ACU).,R.N.M.P.,F.R.I.M.,C.A.M.S.H
Corporate : UHID :
Col Dt. Time : Recv Dt. Time : Sample Type :
Reg Dt. Time : 01-May-2025 07:17 Report Released @ : Report Printed : 01-May-2025 13:32

Abnormal Result(s) Summary

Test Name Result Value Unit Reference Range
Glyco Hemoglobin (HbA1c)
HbA1C 7.70 % Normal : <5.7
Pre diabetes : 5.7-6.4
Diabetes : >6.5
Haemogram (CBC) LAB
RBC Count 3.90 millions/cm 4.5 - 6.5
m
Haemoglobin 12.5 g/dL 13.5 - 18
PCV (Haematocrit) 38.0 % 40 - 54
Mean Corpuscular Volume 97.4 fL 76 - 96
Mean Corpuscular Hemoglobin 32.1 pg 27 - 32
Lipid Profile
HDL Cholesterol 39 mg/dL < 40 - Low Level
40 - 60 - Average Level
> 60 - High Level
NCEP Guidelines ATP III.
Urine Examination
Glucose 1+ mg/dL Negative
Pus Cells 2.9 /HPF 0-2.7 cells/hpf
Uric Acid 28.5 /HPF 0-1.4 p/hpf
Bacteria 35.0 0-29.5 p/hpf
Amorphous Deposits 127.4 0-29.5 p/hpf
Plasma Glucose - F 135 mg/dL Fasting blood glucose : 70 - 99
mg/dl - Normal
100 - 125 mg/dl - Impaired
Fasting :
Diabetic : =>126.
25 OH Cholecalciferol (D2+D3) 19.0 ng/mL Deficient : < 20 ng/mL
Insufficient : 20 - 30 ng/mL
Sufficient : 30 - 100 ng/mL
Toxicity : > 150 ng/mL
Abnormal Result(s) Summary End

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

Page 1 of 11
 Final Laboratory Report PID : 5905991

Name : Mr. JOHN Sex/Age : Male / 52 Years Lab ID : 50526900002

Ref. By : DR.VIJAYALAKSHMI.S M.D SRF ID : Ref. ID :
(ACU).,R.N.M.P.,F.R.I.M.,C.A.M.S.H
Corporate : UHID :
Col Dt. Time : 01-May-2025 07:17 Recv Dt. Time : 01-May-2025 07:17 Sample Type : Whole Blood EDTA
Reg Dt. Time : 01-May-2025 07:17 Report Released @ : 01-May-2025 12:34 Report Printed : 01-May-2025 13:32
TEST RESULTS UNIT BIOLOGICAL REF RANGE TEST REMARK
Complete Blood Counts

RBC Count L 3.90 millions/cmm 4.5 - 6.5

Electrical Impedance

Haemoglobin L 12.5 g/dL 13.5 - 18

SLS Hemoglobin Method

PCV (Haematocrit) L 38.0 % 40 - 54

Pulse Light Detection Method

Mean Corpuscular Volume H 97.4 fL 76 - 96

Calculated

Mean Corpuscular Hemoglobin H 32.1 pg 27 - 32

Calculated

Mean Corpuscular Hb Concentration 32.9 g/dL 30 - 35

Calculated

Red Cell Distribution Width (RDW) 13.0 % 11.5 - 14

Calculated

Total Leucocyte Count(TLC) 8,370 Cells/cmm 4000 - 11000

Flowcytometry

Differential Counts
Neutrophil 51.3 % 40 - 75
Flowcytometry

Lymphocyte 38.0 % 20 - 45
Flowcytometry

Monocytes 7.2 % 2 - 10
Flowcytometry

Eosinophil 3.0 % 1-6

Flowcytometry

Basophil 0.5 % 0-1

Flowcytometry

Absolute Counts
Absolute Neutrophil Count 4294 Cells/cmm 2000-7000
Calculated

Absolute Lymphocyte Count 3181 Cells/cmm 1000-5000

Calculated

Absolute Monocyte Count 603 Cells/cmm 200-1000

Calculated

Absolute Eosinophil Count 251 Cells/cmm 20-500

Calculated

Absolute Basophil Count 42 Cells/cmm 20-100

Calculated

Platelet Count 2,97,000 Cells/cmm 150000 - 400000

Electrical Impedance

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

Sundari.R DR.MONICA KUMBHAT M

MBBS,MD (Pathology) FGIL
Verified by Page 2 of 11 MC-5972
 Final Laboratory Report PID : 5905991

Name : Mr. JOHN Sex/Age : Male / 52 Years Lab ID : 50526900002

Ref. By : DR.VIJAYALAKSHMI.S M.D SRF ID : Ref. ID :
(ACU).,R.N.M.P.,F.R.I.M.,C.A.M.S.H
Corporate : UHID :
Col Dt. Time : 01-May-2025 07:17 Recv Dt. Time : 01-May-2025 07:17 Sample Type : Whole Blood EDTA
Reg Dt. Time : 01-May-2025 07:17 Report Released @ : 01-May-2025 12:34 Report Printed : 01-May-2025 13:32

Mean Platelet Volume (MPV) 9.0 fL 7.2 - 11.7

Calculated

According to ICSH guideline (international Council for Standardisation in Hematology), the differential counts should be
reported in absolute numbers.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

Sundari.R DR.MONICA KUMBHAT M

MBBS,MD (Pathology) FGIL
Verified by Page 3 of 11 MC-5972
 Final Laboratory Report PID : 5905991

Name : Mr. JOHN Sex/Age : Male / 52 Years Lab ID : 50526900002

Ref. By : DR.VIJAYALAKSHMI.S M.D SRF ID : Ref. ID :
(ACU).,R.N.M.P.,F.R.I.M.,C.A.M.S.H
Corporate : UHID :
Col Dt. Time : 01-May-2025 07:17 Recv Dt. Time : 01-May-2025 07:17 Sample Type : Plasma Fluoride F,Whole
Reg Dt. Time : 01-May-2025 07:17 Report Released @ Blood EDTA
:
01-May-2025 12:06 Report Printed : 01-May-2025 13:32
TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

Plasma Glucose - F H 135 mg/dL Fasting blood glucose :

HEXOKINASE/G-6-PDH 70 - 99 mg/dl - Normal
100 - 125 mg/dl -
Impaired Fasting :
Diabetic : =>126.

Glycated Haemoglobin Estimation

HbA1C H 7.70 % Normal : <5.7
HPLC Pre diabetes : 5.7-6.4
Diabetes : >6.5
Estimated Avg Glucose (3 Mths) 174.29 mg/dL Not available
Calculated

Please Note change in reference range as per ADA 2021 guidelines.

Interpretation :
HbA1C level reflects the mean glucose concentration over previous 8-12 weeks and provides better indication of long term glycemic control.
Levels of HbA1C may be low as result of shortened RBC life span in case of hemolytic anemia.
Increased HbA1C values may be found in patients with polycythemia or post splenectomy patients.
Patients with Homozygous forms of rare variant Hb(CC,SS,EE,SC) HbA1c can not be quantitated as there is no HbA.
In such circumstances glycemic control can be monitored using plasma glucose levels or serum Fructosamine.
The A1c target should be individualized based on numerous factors, such as age, life expectancy,comorbid conditions, duration of diabetes,
risk of hypoglycemia or adverse consequences from hypoglycemia, patient motivation and adherence.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO Dr.Selvi R
Consultant Biochemist
Verified by Page 4 of 11 MC-5972
 Final Laboratory Report PID : 5905991

Name : Mr. JOHN Sex/Age : Male / 52 Years Lab ID : 50526900002

Ref. By : DR.VIJAYALAKSHMI.S M.D SRF ID : Ref. ID :
(ACU).,R.N.M.P.,F.R.I.M.,C.A.M.S.H
Corporate : UHID :
Col Dt. Time : 01-May-2025 07:17 Recv Dt. Time : 01-May-2025 07:17 Sample Type : Serum
Reg Dt. Time : 01-May-2025 07:17 Report Released @ : 01-May-2025 12:29 Report Printed : 01-May-2025 13:32
TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

Free T3 2.70 pg/mL 1.58 - 3.91

CMIA

Free T4 0.82 ng/dL 0.70 - 1.48

CMIA

TSH 0.88 µIU/mL 0.35 - 4.94

CMIA

INTERPRETATIONS

• Circulating TSH measurement has been used for screening for euthyroidism, screening and diagnosis for
hyperthyroidism & hypothyroidism. Suppressed TSH (<0.01 µIU/mL) suggests a diagnosis of hyperthyroidism
and elevated concentration (>7 µIU/mL) suggest hypothyroidism. TSH levels may be affected by acute illness
and several medications including dopamine and glucocorticoids. Decreased (low or undetectable) in Graves
disease. Increased in TSH secreting pituitary adenoma (secondary hyperthyroidism), PRTH and in
hypothalamic disease thyrotropin (tertiary hyperthyroidism). Elevated in hypothyroidism (along with decreased
T4) except for pituitary & hypothalamic disease.
• Mild to modest elevations in patient with normal T3 & T4 levels indicates impaired thyroid hormone reserves &
incipent hypothyroidism (subclinical hypothyroidism).
• Mild to modest decrease with normal T3 & T4 indicates subclinical hyperthyroidism.
• Degree of TSH suppression does not reflect the severity of hyperthyroidism, therefore, measurement of free
thyroid hormone levels is required in patient with a supressed TSH level.
CAUTIONS
Sick, hospitalized patients may have falsely low or transiently elevated thyroid stimulating hormone.
Some patients who have been exposed to animal antigens, either in the environment or as part of treatment or
imaging procedure, may have circulating antianimal antibodies present. These antibodies may interfere with the
assay reagents to produce unreliable results.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO Dr.Selvi R
Consultant Biochemist
Verified by Page 5 of 11 MC-5972
 Final Laboratory Report PID : 5905991

Name : Mr. JOHN Sex/Age : Male / 52 Years Lab ID : 50526900002

Ref. By : DR.VIJAYALAKSHMI.S M.D SRF ID : Ref. ID :
(ACU).,R.N.M.P.,F.R.I.M.,C.A.M.S.H
Corporate : UHID :
Col Dt. Time : 01-May-2025 07:17 Recv Dt. Time : 01-May-2025 07:17 Sample Type : Serum
Reg Dt. Time : 01-May-2025 07:17 Report Released @ : 01-May-2025 12:12 Report Printed : 01-May-2025 13:32
TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

Urea 24.20 mg/dL 12.84 - 42.8

Urease

Uric Acid 4.60 mg/dL 3.7 - 7.7

Uricase

Creatinine 0.72 mg/dL 0.6 - 1.3

Kinetic Alkaline Picrate

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO Dr.Selvi R
Consultant Biochemist
Verified by Page 6 of 11 MC-5972
 Final Laboratory Report PID : 5905991

Name : Mr. JOHN Sex/Age : Male / 52 Years Lab ID : 50526900002

Ref. By : DR.VIJAYALAKSHMI.S M.D SRF ID : Ref. ID :
(ACU).,R.N.M.P.,F.R.I.M.,C.A.M.S.H
Corporate : UHID :
Col Dt. Time : 01-May-2025 07:17 Recv Dt. Time : 01-May-2025 07:17 Sample Type : Serum
Reg Dt. Time : 01-May-2025 07:17 Report Released @ : 01-May-2025 12:12 Report Printed : 01-May-2025 13:32
TEST RESULTS UNIT BIOLOGICAL REF RANGE TEST REMARK

Cholesterol 132 mg/dL <200 - Desirable

Enzymatic
200 - 239 - Borderline High
> 240 - High
"NCEP Guidelines ATP III".
Triglyceride 130 mg/dL < 150 - Normal
Glycerol Phosphate Oxidase
150 - 199 - Borderline
200 - 499 - High
> 500 - Very High
"NCEP Guidelines ATP III".
HDL Cholesterol L 39 mg/dL < 40 - Low Level
Accelerator Selective Detergent
40 - 60 - Average Level
> 60 - High Level
NCEP Guidelines ATP III.
LDL Cholesterol 67.00 mg/dL 0 - 100
Calculated

VLDL 26.00 mg/dL <30

Calculated

Non-HDL Cholesterol 93 < 130 Optimal

Calculated
130-159 Near Optimal
160-189 Borderline high
190-219-High
>or = 220- Very high
LDL/HDL Ratio 1.72
Calculated

Chol/HDL 3.38 < 3.5 – Low risk

Calculated
3.5 – 5.0 - Normal risk
> 5.0 - High risk

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO Dr.Selvi R
Consultant Biochemist
Verified by Page 7 of 11 MC-5972
 Final Laboratory Report PID : 5905991

Name : Mr. JOHN Sex/Age : Male / 52 Years Lab ID : 50526900002

Ref. By : DR.VIJAYALAKSHMI.S M.D SRF ID : Ref. ID :
(ACU).,R.N.M.P.,F.R.I.M.,C.A.M.S.H
Corporate : UHID :
Col Dt. Time : 01-May-2025 07:17 Recv Dt. Time : 01-May-2025 07:17 Sample Type : Serum
Reg Dt. Time : 01-May-2025 07:17 Report Released @ : 01-May-2025 12:12 Report Printed : 01-May-2025 13:32
TEST RESULTS UNIT BIOLOGICAL REF RANGE TEST REMARK
LIVER FUNCTION TEST

Bilirubin Total 0.47 mg/dL 0.2 - 1.2

Diazonium Salt

Bilirubin Direct 0.17 mg/dL 0 - 0.5

DIAZO REACTION

Bilirubin Indirect 0.30 mg/dL 0.1 - 1

Calculated

S.G.P.T. 17.00 U/L 0 - 45

NADH (Without P-5-P)

S.G.O.T. 22.00 U/L 11 - 34

NADH (Without P-5-P)

Alkaline Phosphatase 53.00 U/L 40-150

Para-Nitrophenyl Phosphate

Gamma Glutamyl Transferase 36.00 U/L 0 - 55

L-Gamma-glutamyl-3-carboxy-4-nitroanilide
Substrate

Proteins (Total) 7.10 g/dL 6.4 - 8.3

Biuret

Albumin 4.60 g/dL 3.5-5.0

Bromo Cresol Green

Globulin 2.50 g/dL 2.0 - 3.5

Calculated

A/G Ratio 1.8 1.0 - 2.0

Calculated

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO Dr.Selvi R
Consultant Biochemist
Verified by Page 8 of 11 MC-5972
 Final Laboratory Report PID : 5905991

Name : Mr. JOHN Sex/Age : Male / 52 Years Lab ID : 50526900002

Ref. By : DR.VIJAYALAKSHMI.S M.D SRF ID : Ref. ID :
(ACU).,R.N.M.P.,F.R.I.M.,C.A.M.S.H
Corporate : UHID :
Col Dt. Time : 01-May-2025 07:17 Recv Dt. Time : 01-May-2025 07:17 Sample Type : Serum
Reg Dt. Time : 01-May-2025 07:17 Report Released @ : 01-May-2025 12:29 Report Printed : 01-May-2025 13:32
TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

Calcium 9.40 mg/dL 8.4 - 10.2

Arsenazo III

25 OH Cholecalciferol (D2+D3) L 19.0 ng/mL Deficient : < 20 ng/mL

CMIA Insufficient : 20 - 30
ng/mL
Sufficient : 30 - 100
ng/mL
Toxicity : > 150 ng/mL
25-OH-VitD plays a primary role in the maintenance of calcium homeostasis. It promotes intestinal calcium absorption and, in concert with PTH, skeletal
calcium deposition, or less commonly, calcium mobilization. Modest 25-OH-VitD deficiency is common; in institutionalised elderly, its prevalence may be
>50%. Although much less common, severe deficiency is not rare either. Reasons for suboptimal 25-OH-VitD levels include lack of sunshine exposure, a
particular problem in Northern latitudes during winter; inadequate intake; malabsorption (e.g, due to Celiac disease); depressed hepatic vitamin D 25-
hydroxylase activity, secondary to advanced liver disease; and enzyme-inducing drugs, in particular many antiepileptic drugs, including phenytoin,
phenobarbital, and carbamazepine, that increase 25-OH-VitD metabolism. Hypervitaminosis D is rare, and is only seen after prolonged exposure to
extremely high doses of vitamin D. When it occurs, it can result in severe hypercalcemia and hyperphosphatemia.

INTERPRETATION
• Levels <10 ng/mL may be associated with more severe abnormalities and can lead to inadequate mineralization of newly formed osteoid, resulting
in rickets in children and osteomalacia in adults. In these individuals, serum calcium levels may be marginally low, and parathyroid hormone (PTH)
and serum alkaline phosphatase are usually elevated. Definitive diagnosis rests on the typical radiographic findings or bone
biopsy/histomorphometry.
• Patients who present with hypercalcemia, hyperphosphatemia, and low PTH may suffer either from ectopic, unregulated conversion of 25-OH-VitD
to 1,25 (OH)2-VitD, as can occur in granulomatous diseases, particularly sarcoidosis, or from nutritionally-induced hypervitaminosis D. Serum 1,25
(OH)2-VitD levels will be high in both groups, but only patients with hypervitaminosis D will have serum 25-OH-VitD concentrations of >80 ng/mL,
typically >150 ng/mL.
• Patients with CKD have an exceptionally high rate of severe vitamin D deficiency that is further exacerbated by the reduced ability to convert 25-
OH- VitD into the active form, 1,25 (OH)2-VitD. Emerging evidence also suggests that the progression of CKD & many of the cardiovascular
complications may be linked to hypovitaminosis D.
• Approximately half of Stage 2 and 3 CKD patients are nutritional vitamin D deficient (25-OH-VitD, less than 30 ng/mL), and this deficiency is more
common among stage 4 CKD patients. Additionally, calcitriol (1,25 (OH)2-VitD) levels are also overtly low (less than 22 pg/mL) in CKD patients.
Similarly, vast majority of dialysis patients are found to be deficient in nutritional vitamin D and have low calcitriol levels. Recent data suggest an
elevated PTH is a poor indicator of deficiencies of nutritional vitamin D and calcitriol in CKD patients.CAUTIONS Long term use of anticonvulsant
medications may result in vitamin D deficiency that could lead to bone disease; the anticonvulsants most implicated are phenytoin, phenobarbital,
carbamazepine, and valproic acid.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO Dr.Selvi R
Consultant Biochemist
Verified by Page 9 of 11 MC-5972
 Final Laboratory Report PID : 5905991

Name : Mr. JOHN Sex/Age : Male / 52 Years Lab ID : 50526900002

Ref. By : DR.VIJAYALAKSHMI.S M.D SRF ID : Ref. ID :
(ACU).,R.N.M.P.,F.R.I.M.,C.A.M.S.H
Corporate : UHID :
Col Dt. Time : 01-May-2025 07:17 Recv Dt. Time : 01-May-2025 07:17 Sample Type : Urine
Reg Dt. Time : 01-May-2025 07:17 Report Released @ : 01-May-2025 13:27 Report Printed : 01-May-2025 13:32
TEST RESULTS UNIT BIOLOGICAL REF RANGE TEST REMARK

Urine Routine Examination

Appearance Very turbid Clear
Automated - Light Scattering

Colour Yellow Straw to Yellow

Automated - Light Scattering

pH 5.0 5-9
Indicator

Sp.Gravity 1.022 1.000-1.030

Refractive Index

Chemical Examination
Protein Negative mg/dL Negative
Reflectance Photometry (Protein Error of
Principle indicator)

Glucose 1+ mg/dL Negative

Reflectance Photometry - Glucose Oxidase &
Peroxidase

Bile pigment Negative mg/dL Negative

Fouchet`s test

Urobilinogen Not increased mg/dL 0-2 mg/dl

Coupling of Urobilinogen with stabilized
Diazonium Salt

Ketones Negative mg/dL Negative

Reflectance Photometry - Sodium Nitroprusside

Nitrite Negative mg/dL Negative

Griess Reaction

Microscopic Examination
Red Blood Cell 0.0 /HPF 0-2.3 cells/hpf
Pus Cells 2.9 /HPF 0-2.7 cells/hpf
Epithelial Cell 0.0 /HPF 0-1.1 cells/hpf
Cast 0.0 /HPF 0-0.5 p/hpf
Pathological Cast 0.0 /HPF NIL
Reflectance Photometry

Crystals
Calcium oxalate Monohydrate 1.5 /HPF Nil
Calcium oxalate Dihydrate 0.0 /HPF Nil
Triple phosphate 0.0 /HPF Nil
Uric Acid H 28.5 /HPF 0-1.4 p/hpf
Phase Contrast Microscopy (Sedimentation
based with AIEM)

Bacteria 35.0 0-29.5 p/hpf

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO DR.MONICA KUMBHAT M

MBBS,MD (Pathology) FGIL
Verified by Page 10 of 11 MC-5972
 Final Laboratory Report PID : 5905991

Name : Mr. JOHN Sex/Age : Male / 52 Years Lab ID : 50526900002

Ref. By : DR.VIJAYALAKSHMI.S M.D SRF ID : Ref. ID :
(ACU).,R.N.M.P.,F.R.I.M.,C.A.M.S.H
Corporate : UHID :
Col Dt. Time : 01-May-2025 07:17 Recv Dt. Time : 01-May-2025 07:17 Sample Type : Urine
Reg Dt. Time : 01-May-2025 07:17 Report Released @ : 01-May-2025 13:27 Report Printed : 01-May-2025 13:32

Yeast 0.0 0-0.7 p/hpf

Amorphous Deposits 127.4 0-29.5 p/hpf

------------------ End Of Report ------------------

# For test performed on specimens received or collected from non-NDPL locations, it is presumed that the specimen belongs to the patient named or identified as labeled
on the container/test request and such verification has been carried out at the point generation of the said specimen by the sender. NDPL will be responsible Only for the
analytical part of test carried out. All other responsibility will be of referring Laboratory.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO DR.MONICA KUMBHAT M

MBBS,MD (Pathology) FGIL
Verified by Page 11 of 11 MC-5972